Corrigendum to "A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus" [Drug Alcohol Depend. 93(1-2) (2008) 148-154] (DOI:10.1016/j.drugalcdep.2007.09.011);A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus

Drug and Alcohol Dependence

Volumn 93, Issue 1-2, 2008, Pages 148-154

  Currie, Sue L ^a   Ryan, James C ^a,b   Tracy, Daniel ^a   Wright, Teresa L ^b   George, Sally ^b   McQuaid, Rosemary ^b   Kim, Michael ^a,b   Shen, Hui ^a   Monto, Alexander ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HCV reinfection; HCV resolution; Hepatitis; Hepatitis C Virus; IDUs

Indexed keywords

ANTIVIRUS AGENT; VIRUS ANTIBODY; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEXUAL BEHAVIOR;

HEPATITIS C VIRUS;

EID: 36849005374     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.02.001     Document Type: Erratum

References (19)

1. Alter M.J., Kruszon-Moran D., and Nainan O.V. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Eng. J. Med. 341 (1999) 556-562
2. Armstrong G., Wasley A., Simard E., McQuillan G., Kuhnert W., and Alter M. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144 (2006) 705-714
3. Bassett S., Guerra B., Brasky K., Miskovsky E., Houghton M., Klimpel G.R., and Lanford R.E. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 (2001) 1479-1487
4. Bini E., Currie S., Shen H., and for the VA-HCV-001 Group. National multicenter study of HIV testing and HIV seropositivity in patients with chronic hepatitis C virus infection. J. Clin. Gastroenterol. 40 (2006) 732-739
5. Cooper S., Erickson A., Adams E., Kansopon J., Weiner A., Chien D., Houghton M., Parham P., and Walker C. Analysis of a successful immune response against hepatitis C virus. Immunity 10 (1999) 439-449
6. Dalgard O., Bjoro K., Hellum K., Myrvang B., Skaug K., Gutigard B., Bell H., and for the Construct group. Treatment of chronic hepatitis C in injecting drug users: 5 years follow-up. Eur. Addict. Res. 8 (2002) 45-49
7. Davis G.L., Albright J.E., Cook S.F., and Rosenberg D.M. Projecting future complications of chronic hepatitis C in the United States. Liver Transplant. 9 (2003) 331-338
8. Farci P., Alter H.J., Govindarajan S., Wong D.C., Engle R., Lesniewski R.R., Mushahwar I.K., Desai S.M., Miller R.H., Ogata N., and Purcell R.H. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 (1992) 135-140
9. Golub, E., Strathdee, S., Bailey, S., Hagan, H., Latka, M., Hudson, S., Garfein, S., 2007. Distributive syringe exchange sharing among young adult injection drug users in five US cities. Drug Alcohol Depend. doi 10.1016.
10. Grebely J., Conway B., Raffa J., Lai C., Krajden M., and Tyndall M. Hepatitis C virus reinfection in injection drug users. Hepatology 44 (2006) 1139-1145
11. Lum P., Sears C., and Guydish J. Injection risk behavior among women syringe exchangers in San Francisco. Subst. Use Misuse 40 (2005) 1681-1696
12. Mehta S., Cox A., Hoover D., Xiao-Hong W., Mao Q., Ray S., Strathdee S., and Thomas D. Protection against persistence of hepatitis C. Lancet 359 (2002) 1478-1483
13. Micallef J., Macdonald V., Jauncey M., Amin J., Rawlinson W., van Beek I., Kaldor J.M., White P.A., and Dore G.J. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J. Viral Hepat. 14 (2007) 413-418
14. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002. Hepatology 36 (2002) S3-S20
15. Orland J., Wright T., and Cooper S. Acute hepatitis C. Hepatology 33 (2001) 321-327
16. Quiroga J., Llorente S., Castillo I., Rodriguez-Inigo E., Lopez, Alcorocho J., Pardo M., and Carreno V.F. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J. Med. Virol. 78 (2006) 1190-1197
17. Spaulding A., Weinbaum C., Lau D., Sterling R., Seeff L., Margolis H., and Hoofnagle J. A framework for management of hepatitis C in prisons. Ann. Intern. Med. 144 (2006) 762-769
18. Strader D.B., Wright T.L., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
19. Yee H.S., Currie S., Darling J., and Wright T.L. Management and treatment of hepatitis C viral infection: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program office. Am. J. Gastroenterol. 101 (2006) 2360-2378